We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$531M
AUM Growth
-$19.6M
Cap. Flow
-$36.7M
Cap. Flow %
-6.9%
Top 10 Hldgs %
30.22%
Holding
139
New
9
Increased
20
Reduced
40
Closed
15

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$8.09M
2
SYK icon
Stryker
SYK
+$5.81M
3
AMSG
Amsurg Corp
AMSG
+$5.72M
4
ABMD
Abiomed Inc
ABMD
+$5.69M
5
HOLX
Hologic
HOLX
+$5.45M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$6.82M
2
BDX icon
Becton Dickinson
BDX
+$6.76M
3
BIIB icon
Biogen
BIIB
+$5.81M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$4.91M
5
INSY
Insys Therapeutics, Inc.
INSY
+$4.49M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
126
Cencora
COR
$59.9B
– –
-34,000
Closed -$2.94M
DXCM icon
127
DexCom
DXCM
$29.6B
– –
-80,000
Closed -$1.36M
EGBN icon
128
Eagle Bancorp
EGBN
$835M
– –
-93,400
Closed -$3.78M
GERN icon
129
Geron
GERN
$924M
– –
-45,000
Closed -$131K
PTCT icon
130
PTC Therapeutics
PTCT
$6.52B
– –
-35,000
Closed -$225K
XOMA
131
DELISTED
Xoma
XOMA
– –
-11,250
Closed -$174K
IMGN
132
DELISTED
Immunogen Inc
IMGN
– –
-30,000
Closed -$256K
LCI
133
DELISTED
Lannett Company, Inc.
LCI
– –
-26,953
Closed -$1.93M
CLVS
134
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-52,500
Closed -$1.01M
INSY
135
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-281,000
Closed -$4.49M
ECYT
136
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-100,000
Closed -$310K
BTX.WS
137
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
– –
-2,294
Closed -$1K
JNP
138
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
– –
-50,000
Closed -$331K
AST
139
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
– –
-1,875
Closed -$9K
2 3 4 5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2016 Portfolio in Review

As of Q2 2016, Bellevue Group held 139 positions worth $531M, down 3.6% from $551M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group withdrew a net $36.7M in Q2 2016, closing 15 positions and reducing 40 holdings. Its most notable exit was Insys Therapeutics, Inc., an estimated $4.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Allergan plc worth $8.11M.

  • Bellevue Group's largest Q2 2016 buy was Allergan plc: 35,100 shares worth $8.11M.
  • Bellevue Group added most to Stryker in Q2 2016, an estimated $5.81M increase.
  • Bellevue Group's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $6.82M.
  • Bellevue Group fully exited Insys Therapeutics, Inc. in Q2 2016, selling an estimated $4.49M.
  • Bellevue Group's ten largest holdings make up 30% of its $531M portfolio in Q2 2016.
  • Bellevue Group opened 9 new positions and closed 15 in Q2 2016.
  • Bellevue Group's portfolio value fell 3.6% quarter-over-quarter to $531M.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.